BioAge Labs, Inc. BIOA
5.78 USD +0.09 (+1.58%)
At closeNov 10, 2026, 4:01 PM EST
5.78 0.00 0.00%
After hours · Nov 10, 4:01 PM ET
5.54 Day range 5.90
4.81 52-week range 25.96
- YTD
- -56.31%
- 1 year
- -22.83%
News
benzinga.com Piper Sandler Maintains Overweight on Bioage Labs, Lowers Price Target to $40 Piper Sandler analyst Yasmeen Rahimi maintains Bioage Labs (NASDAQ:BIOA) with a Overweight and lowers the price target from $73 to $40.
zacks.com BioAge Labs, Inc. (BIOA) Reports Q3 Loss, Misses Revenue Estimates BioAge Labs, Inc. (BIOA) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to a loss of $0.56 per share a year ago.
benzinga.com Bioage Labs Q3 EPS $(0.73) Misses $(0.59) Estimate, Sales $298.000K Miss $1.644M Estimate Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.59) by 23.73 percent. This is a 30.36 percent decrease over losses of…
globenewswire.com BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates First participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results anticipated in the second half of 2027
benzinga.com BioArctic AB Announces Novartis Terminates Their 2025 Option, Collaboration And License Deal; BioArctic To Retain Full $30M Upfront Payment BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that Novartis Pharma AG has notified BioArctic that it has decided to terminate the Option, Collaboration and License Agreement entered…
zacks.com Earnings Preview: BioAge Labs, Inc. (BIOA) Q3 Earnings Expected to Decline BioAge Labs, Inc. (BIOA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
defenseworld.net BioAge Labs (NASDAQ:BIOA) and Royalty Pharma (NASDAQ:RPRX) Critical Comparison BioAge Labs (NASDAQ: BIOA - Get Free Report) and Royalty Pharma (NASDAQ: RPRX - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies…
globenewswire.com Deep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First Target Partnership applies Deep Origin's virtual screening architecture to BioAge's targets, identified from human data, to accelerate discovery of novel cardiometabolic therapies Partnership applies Deep…
benzinga.com UBS Initiates Coverage On Bioage Labs with Neutral Rating, Announces Price Target of $8 UBS analyst Alice Nettleton initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Neutral rating and announces Price Target of $8.
defenseworld.net Bank of America Corp DE Buys 257,855 Shares of BioAge Labs, Inc. $BIOA Bank of America Corp DE acquired a new position in shares of BioAge Labs, Inc. (NASDAQ: BIOA) in the undefined quarter, according to the company in its most recent disclosure with the Securities and…
globenewswire.com BioAge Labs to Present at Upcoming Investor Conferences EMERYVILLE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for…
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
seekingalpha.com BioAge Labs, Inc. (BIOA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript BioAge Labs, Inc. (BIOA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com BioAge Labs, Inc. (BIOA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript BioAge Labs, Inc. (BIOA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript- benzinga.com BioAge Labs Doses First Patient In Its Phsae 2 Study Of BGE-102 To Treat Diabetic Macular Edema BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge" or the "Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the…
globenewswire.com BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema Randomized, controlled, approximately 180-participant trial evaluates oral BGE-102 as monotherapy and in combination with anti-VEGF therapy Primary endpoint is change in best-corrected visual acuity…
seekingalpha.com BioAge: CV Risk Data Due H2 A Major Catalyst After Rival's Data Causes Sell-Off BioAge Labs remains a buy despite a >40% stock drop, as the recent sell-off appears overblown given competitive Phase 1 data for BGE-102. BGE-102, a best-in-class NLRP3 inhibitor, achieved up to 98%…
globenewswire.com BioAge Labs to Present at Upcoming Investor Conferences EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for…
defenseworld.net 214,546 Shares in BioAge Labs, Inc. $BIOA Purchased by Dimensional Fund Advisors LP Dimensional Fund Advisors LP acquired a new position in BioAge Labs, Inc. (NASDAQ: BIOA) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange…
zacks.com BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates BioAge Labs, Inc. (BIOA) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.6 per share a year ago.- benzinga.com Bioage Labs Q2 EPS $(0.58) Beats $(0.60) Estimate, Sales $2.451M Beat $1.920M Estimate Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.60) by 3.33 percent. This is a 3.33 percent increase over losses of $(0.60)…
globenewswire.com BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of 2026- benzinga.com Needham Maintains Buy on Bioage Labs, Lowers Price Target to $35 Needham analyst Joseph Stringer maintains Bioage Labs (NASDAQ:BIOA) with a Buy and lowers the price target from $50 to $35.
benzinga.com Why Is BioAge Labs Stock Sinking Friday? BioAge Labs Inc. (NASDAQ:BIOA) stock plunged Friday after disappointing Phase 3 cardiovascular trial results from Novo Nordisk A/S (NYSE:NVO) sparked concerns about the potential of NLRP3-targeting…
benzinga.com Why Is BioAge Labs Stock Sinking Friday? BioAge Labs stock plummeted as failed Phase 3 ZEUS trial data from Novo Nordisk sparked broad concerns for NLRP3-targeting therapies.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular session. SCYNEXIS (NASDAQ:SCYX) stock moved upwards by 22.54% to $4.57. The market value of their outstanding…
benzinga.com Nasdaq Surges 300 Points; Amazon Shares Jump Following Upbeat Earnings US stocks rise, Nasdaq up 300 points. Dow up 0.36%, Nasdaq up 1.31%, S&P 500 up 0.65%. Amazon shares jump 14% after posting strong Q2 results.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-market session. Moleculin Biotech (NASDAQ:MBRX) shares increased by 17.64% to $1.2. The market value of…
defenseworld.net BioAge Labs (NASDAQ:BIOA) Trading Up 5.5% – Should You Buy? BioAge Labs, Inc. (NASDAQ: BIOA - Get Free Report)'s stock price rose 5.5% on Friday. The stock traded as high as $23.09 and last traded at $23.3710. Approximately 51,852 shares changed hands during…
benzinga.com BioAge Labs Doses First Participant Dosed In QUELL-CV Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular…
globenewswire.com BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular…
seekingalpha.com BioAge Labs, Inc. (BIOA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript BioAge Labs, Inc. (BIOA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
benzinga.com This GE Aerospace Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Top Wall Street analysts changed outlook on top names. See analyst ratings page for upgrades, downgrades, and initiations. Check out what analysts think of GE stock.
benzinga.com Roth Capital Initiates Coverage On Bioage Labs with Buy Rating, Announces Price Target of $36 Roth Capital analyst Adam Walsh initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Buy rating and announces Price Target of $36.
benzinga.com This CoinShares Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Wednesday Wall Street analysts changed outlook on top stocks. Check our analyst ratings page for all changes. See opinions on CSHR, BIOA.- benzinga.com BTIG Initiates Coverage On Bioage Labs with Buy Rating, Announces Price Target of $40 BTIG analyst Thomas Shrader initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Buy rating and announces Price Target of $40.
benzinga.com Bioage Labs Q1 EPS $(0.52) Beats $(0.64) Estimate, Sales $2.772M Beat $1.083M Estimate Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.64) by 18.75 percent. This is a 44.44 percent decrease over losses of $(0.36)…
benzinga.com BioAge Labs Stock Gains After Positive Early Data And Pipeline Plans BioAge Labs says BGE-102 Phase 1 data show strong hsCRP reductions at 60 mg and 120 mg; analysts maintain Buy ratings with higher targets.
benzinga.com Fastenal, Replimune Group, Children's Place And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures lower, with Dow futures down 150 points. Fastenal shares dip 4% after meeting earnings estimate. Other stocks also down.
benzinga.com This Honeywell Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Wall Street analysts change outlook on top names. Check analyst ratings page for upgrades, downgrades, and initiations. See others' views on these stocks.- benzinga.com Needham Initiates Coverage On Bioage Labs with Buy Rating, Announces Price Target of $50 Needham analyst Joseph Stringer initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Buy rating and announces Price Target of $50.
- benzinga.com Bioage Labs Q4 EPS $(0.72) Beats $(0.73) Estimate, Sales $3.078M Beat $1.915M Estimate Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.73) by 1.37 percent. This is a 22.03 percent decrease over losses of $(0.59)…
- benzinga.com Citigroup Maintains Buy on Bioage Labs, Raises Price Target to $52 Citigroup analyst Samantha Semenkow maintains Bioage Labs (NASDAQ:BIOA) with a Buy and raises the price target from $15 to $52.
benzinga.com This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - benzinga.com Oppenheimer Initiates Coverage On Bioage Labs with Outperform Rating, Announces Price Target of $60 Oppenheimer analyst Jay Olson initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Outperform rating and announces Price Target of $60.
benzinga.com This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday 
benzinga.com Jefferies Upgrades Bioage Labs to Buy, Raises Price Target to $62 Jefferies analyst Roger Song upgrades Bioage Labs (NASDAQ:BIOA) from Hold to Buy and raises the price target from $9 to $62.- benzinga.com Piper Sandler Initiates Coverage On Bioage Labs with Overweight Rating, Announces Price Target of $73 Piper Sandler analyst Yasmeen Rahimi initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Overweight rating and announces Price Target of $73.
- benzinga.com Reported Earlier, BioAge Prices Upsized $115M Public Offering Of 5.9M Shares At $19.50 Per Share BioAge intends to use the net proceeds from the proposed offering, together with its existing cash, cash equivalents and marketable securities, to fund research, clinical and process development and…
benzinga.com Netflix, Erasca, Kraft Heinz And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session